• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Alcami

    Emergent BioSolutions

    Almac Group

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Alcami

    Emergent BioSolutions

    Adare Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Rapid Delivery of Medical Countermeasures Amid Pandemic

    Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines

    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Rapid Delivery of Medical Countermeasures Amid Pandemic
    Photo courtesy of iBio, Inc.
    Kristin Brooks, Contract Pharma04.03.20

    Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challenges in a pandemic setting.

    iBio, Inc., a biologics CMO and biotechnology company, is working to develop vaccine candidates to prevent infection from the SARS-CoV-2 virus that causes COVID-19 disease.
     
    iBio created its SARS-CoV-2 Virus-Like Particle (VLP)-based constructs in just a few weeks using its FastPharming System to produce the nanoparticles in, and purify them from, plants. The manufacturing platform allows for rapid development of research quantities of product, as well as high-quality material that is readily scalable for producing doses for clinical trials and commercial use.
     
    Originally built in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense, iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic. The factory is equipped with automated hydroponics and vertical farming systems for the production of a wide array of biological medicines using a relative of the tobacco plant as the “bioreactor.”

    Contract Pharma spoke with Robert L. Erwin, President of iBio, Inc. about the manufacturing platform and potential timeline for the delivery of COVID-19 medical countermeasures. –KB
     

    Contract Pharma: Please describe iBIO’s manufacturing platform being leveraged to develop vaccine candidates.

    Robert Erwin: iBio’s FastPharming System uses plants as bioreactors, rather than traditional mammalian or microbial cell culture bioprocesses. The plant bioreactors are grown in a specially designed, optimized, and controlled indoor vertical farm environment employing large-scale hydroponics and LED lighting tuned for consistent growth. The gene encoding the specific protein of interest is cloned into a plant-specific expression vector and transfected into Agrobacterium tumifaciens. The expression vector housed within Agrobacterium is then delivered into the leaves of iBio’s proprietary Nicotiana benthamiana plants, which are close relatives of common tobacco plants, by a process called vacuum infiltration. After infiltration, the target protein is expressed in the leaves and, approximately one week later, high-throughput harvest of the leaves is followed by extraction of the target protein, purification, formulation into the desired final product, and appropriate fill/finish processes.

    Transient plant-based production significantly reduces the time and cost associated with: (i) the initial upstream setup and execution, (ii) production scale-up, and (iii) characterization and quality assessments compared with conventional bioproduction methods. As each plant serves as a standalone bioreactor, there is a very high degree of consistency between material produced at the research stage and commercial-scale production, and scaling to any level can be directly achieved by simply growing more plants. The FastPharming platform provides confidence that critical consistency is maintained under the accelerated timelines for vaccine and/or therapeutic development and manufacturing during a pandemic.

    COVID-19–related vaccines and therapeutics may further require tight control of glycosylation patterns modified from typical human forms. iBio’s FastGlycaneering Technology facilitates such control of posttranslational modifications, with proprietary transgenic plants that demonstrate customized and finely tuned glycosylation patterns.

    CP: What development progress have you seen thus far and do you anticipate any specific challenges going forward?

    RE: iBio’s FastPharming Technology has been previously deployed for development, manufacture, and evaluation of vaccine candidates for viral and bacterial pathogens in clinical trials. That experience was rapidly put to use in January to design, express, and produce COVID-19 vaccine candidates. These candidates are undergoing additional development to select a lead candidate and formulation for extensive animal testing and initial human clinical evaluation. Based on existing data and experience, we do not anticipate manufacturing challenges, and we believe most safety questions can be addressed within a matter of weeks.

    CP: What are the major challenges conducting clinical trials during this pandemic?

    RE: There are a myriad of challenges to the manufacturing and clinical trial supply chain already occurring, with likely broader impacts that will continue to ripple across the industry. Efficient clinical trials require the coordination of supply of not only the experimental drugs, but also comparator drugs, ancillary supplies, and laboratory equipment. These are overlaid with proper clinical packaging, oversight of blinding, and the protection of patient data. Bottlenecks in supply chain links to any of the relevant supplies can potentially compromise a clinical trial, and shortages of even simple routine supplies –– like surgical gloves and masks –– have already manifested.

    Additionally, there are growing concerns about the risks of exposure of vulnerable, potentially immunocompromised patients to SARS-CoV-2 at traditional clinical trials centers, and as such the need for direct-to-patient (DTP) clinical trials models and associated services have become even more acute. Clinical trial logistics organizations are already being tested to secure the supply of existing DTP trials, and this will grow as more previously centralized trials transition into DTP models. Many clinical trials unrelated to COVID-19 have been delayed or even suspended within the last two weeks.

    CP: What is the potential timeline for the delivery of medical countermeasures in response to the COVID-19 pandemic?

    RE: Aside from protective equipment for healthcare workers, diagnostic tests, and critical care equipment, all of which have seen significant delivery shortfalls, there are still opportunities for government and industry partnerships, to speed the development, testing, and delivery of therapeutic and protective (i.e., vaccine) countermeasures to combat the COVID-19 pandemic.

    Some therapeutics can be repurposed from applications already approved by the FDA and are in clinical trials already, with mixed success to date. More promising experimental therapeutics are in various stages of early development, and the FDA has created accelerated review pathways to facilitate rapid initiation of clinical trials. The timelines for delivery of promising experimental therapeutics depend on the rate at which patients are accrued to clinical trials, the efficacy and safety of the novel drugs, and the speed with which cGMP manufacturing capacity can be developed or accessed. The better of these new drug candidates are likely to be used in emergency treatment in parallel with careful evaluation of their safety and efficacy in patients who are not critically ill. Conditional FDA approvals, if supported by compelling clinical data, could occur as soon as this year.

    Vaccines represent a different challenge in that they must be safe enough to administer to healthy people who may or may not be at risk of infection. This requires careful, early clinical evaluation followed by more extensive testing in larger groups to assess the protective value of a new vaccine. The FDA has already selectively relaxed requirements for preclinical safety evaluation of vaccine candidates for SARS-CoV-2 prior to approving initiation of human clinical trials.

    iBio’s plant-based vaccine candidates combine two of the critical features required for rapid deployment. The first is a formulation that is likely to rapidly prove to be safe and effective, based on prior experience with plant-based VLPs tested against other targets and current knowledge of vaccine design alternatives intended to be effective in stimulation of a protective immune response. The second critical feature enabling rapid delivery of iBio’s vaccine countermeasure(s) is the combination of FastPharming technology with iBio’s cGMP manufacturing facility. Together, these are capable of assuring delivery of millions of doses of vaccine every month beginning immediately upon FDA approval, much faster than traditional approaches to manufacture of protein subunit vaccines.
     


    Robert Erwin is President of iBio, Inc. Prior to iBio, Robert led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000 and was Chairman of Icon Genetics AG from its founding through its sale to Bayer AG in 2006. Mr. Erwin has extensive experience in clinical trial design and has served in advisory positions with a number of organizations including the Cancer Policy Forum of the Institute of Medicine, the Research Committee of the American Society of Clinical Oncology, the Data and Safety Monitoring Board of the Nat’l. Cancer Institute’s Cancer and Leukemia Group B, the Clinical Development Advisory Board of the California Institute for Regenerative Medicine, and the Compassionate Use Advisory Committee of the New York University School of Medicine.
    Related Searches
    • Pharma
    • Logistics
    • biotechnology
    • facility

    Related Online Exclusives

    • Clinical Trials | Drug Development | QA/QC
      RBQM Comes of Age: COVID as a Catalyst for Change

      RBQM Comes of Age: COVID as a Catalyst for Change

      Clinical trial conduct has undergone a fundamental shift over the last year – and things will never be the same again.
      Kristin Brooks, Managing Editor 04.01.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture
      Advanced Analytics Advancing Development of Genetic Vaccines

      Advanced Analytics Advancing Development of Genetic Vaccines

      Leveraging innovative advanced analytical technologies to ensure regulatory compliance in the development and production of novel vaccines.
      Kristin Brooks, Managing Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a COVID Vaccine Trial

      Inside a COVID Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

    • Clinical Trials | Information Technology
      The State of Clinical Trial Technology

      The State of Clinical Trial Technology

      Blake Adams of Florence discusses key report findings and the clinical trial software used to support Pfizer’s global COVID-19 vaccine study.
      Kristin Brooks, Contract Pharma 01.26.21

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21


    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20

    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20


    • Biologics, Proteins, Vaccines
      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      CMOs expand and ‘repurpose’ capacities.
      S Harachand, Contributing Editor 10.20.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20


    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20

    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Biologics, Proteins, Vaccines | Drug Discovery
      Cell Therapy for Solid Tumors

      Cell Therapy for Solid Tumors

      Is base editing the solution for solid tumor-based cell therapy?
      Jonathan Frampton, Corporate Development Partner, Horizon Discovery 06.26.20

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login